Audentes Therapeutics Announces Co-Founder and Chief Executive Officer Matthew R. Patterson Appointed Chairman of the Alliance for Regenerative Medicine
SAN FRANCISCO, Oct. 3, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-Founder and Chief Executive Officer (CEO) Matthew R. Patterson has been appointed Chairman of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. Mr. Patterson has served as Vice Chairman of ARM since August 2016.
"Today's announcement is the natural progression of the important contributions that Matt has made through multiple leadership roles at the Alliance for Regenerative Medicine," stated Janet Lynch Lambert, CEO of ARM. "Matt brings significant expertise in the development of novel therapies for rare genetic disorders that address serious, life-threatening rare diseases, and his deep entrepreneurial experience and track record of success are valued by the ARM leadership team."
Prior to his role as Vice Chairman, Mr. Patterson was a member of the board of directors at ARM. In his various leadership positions, Mr. Patterson has been responsible for the support and promotion of ARM's global strategy to increase funding for the research and development of advanced gene and cell-based therapies, as well as addressing industry issues around regulatory science and reimbursement to support marketing approval and commercial acceptance of safe and effective regenerative medicine products.
"The Alliance for Regenerative Medicine advocates for progress in gene therapy, cell therapy, and tissue engineering, and I am deeply committed to this mission," said Mr. Patterson. "ARM provides a critical forum to ensure the successful development and future availability of innovative new treatments for patients, and I welcome the opportunity to expand my leadership role within the organization."
Mr. Patterson has 25 years of experience in the research, development, and commercialization of innovative treatments for rare diseases and has held positions of senior management in both private and public biotechnology companies. He is the co-founder of Audentes and has served as CEO since the Company's inception in November 2012. Previously, Mr. Patterson worked for Amicus Therapeutics, BioMarin Pharmaceutical, and Genzyme Corporation. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed, the world's largest health-care dedicated investment firm.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 300 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases. We are currently conducting Phase 1/2 clinical studies of our lead product candidates, AT132 for the treatment of XLMTM, and AT342 for the treatment of Crigler-Najjar syndrome. We have two additional product candidates in development, including AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.
For more information regarding Audentes, please visit www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
[email protected]
Media Contact:
Katie Hogan
415.951.3398
[email protected]
SOURCE Audentes Therapeutics, Inc.
Share this article